Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab in Neovascular Age-Related Macular Degeneration
NCT06795048Phase 4Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 4 trial of faricimab in neovascular age-related macular degeneration (NVAMD), sponsored by Roche. Started Mar 2025; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06795048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795048.